Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 20/20 | 0.46 |
| ▸ | MMP13 | P45452 | 17/20 | 0.46 |
| ▸ | MMP1 | P03956 | 9/20 | 0.46 |
| ▸ | MMP9 | P14780 | 7/20 | 0.46 |
| ▸ | MMP2 | P08253 | 6/20 | 0.46 |
| ▸ | MMP7 | P09237 | 2/20 | 0.46 |
| ▸ | MMP8 | P22894 | 2/20 | 0.46 |
| ▸ | MMP14 | P50281 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503726 | 0.77 | ADAM17 (0.52) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6502911 | 0.75 | ADAM17 (0.54) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6626306 | 0.74 | ADAM17 (0.56) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6754073 | 0.72 | ADAM17 (0.46) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6754071 | 0.72 | ADAM17 (0.46) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6504803 | 0.71 | ADAM17 (0.54) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7388507 | 0.71 | ADAM17 (0.52) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6769034 | 0.71 | ADAM17 (0.52) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6506927 | 0.71 | ADAM17 (0.59) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6503917 | 0.69 | ADAM17 (0.53) | ADAM17MMP13MMP1MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812227-B2 | SULFUR COMPOUNDS SUCH AS 2-((4-BUT-2-YNYLOXY-BENZENESULFONYL)-METHYL-AMINO)-N-HYDROXY-3-METHYL -BUTYRAMIDE, USED AS TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) INHIBITORS, FOR PROPHYLAXIS OF RHEUMATIC DISEASES, SEPSIS OR INFLAMMATION | WYETH HOLDINGS CORPORATION | 2004-11-02 | — | — | US | disclosed |
| US-6716833-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, SEPSIS, AIDS, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, CROHN'S DISEASE AND DEGENERATIVE CARTILAGE LOSS. | WYETH HOLDINGS CORPORATION | 2004-04-06 | — | — | US | disclosed |